EUCTR2013-003388-79-ES进行中（未招募）1 期
PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBINUTUZUMAB (RO5072759) + BENDAMUSTINE TREATMENT IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Roche Farma, S.A.0 个研究点目标入组 72 人开始时间: 2013年12月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Age 18 years or older
- •2.Have documented CD20+ B-CLL according to NCI criteria (see Appendix 2)
- •3.Active disease meeting at least 1 of the following IWCLL 2008 criteria for requiring treatment:
- •a)Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (Hgb < 10 g/dL) and/or thrombocytopenia (platelets < 100,000/µL)
- •b)Massive (i.e. at least 6 cm bellow the left costal margin), progressive or symptomatic splenomegaly
- •c)Massive nodes (i.e. at least 10 cm in the longest diameter), progressive or symptomatic lymphadenopathy
- •d)Progressive lymphocytosis with an increase of more than 50% over a 2-month period or a lymphocyte doubling time (LDT) of less than 6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte counts (ALC) obtained at intervals of 2 weeks over an observation period of 2-3 months. In patients with initial blood lymphocyte counts of less than 30 x 109/L (30,000/µL), LDT should not be used as a single parameter to define indication for the treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infections) should be excluded,
- •e)Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy
- •f)Constitutional symptoms documented in the patient´s chart with supportive objective measures, as appropriate, defined as one or more of the following disease-related symptoms or signs:
- •i.Unintentional weight loss > 10% within the previous 6 months prior to Screening
- •ii.Fever higher than 38.0ºC for 2 or more weeks prior to Screening without evidence of infection
- •iii.Night sweats for more than 1 month prior to Screening without evidence of infection.
- •4.Refractory CLL (i.e. treatment failure or progression within 6 months of treatment) or relapse CLL (i.e. patient who met criteria for CR or PR, but progressed beyond 6 months post-treatment).
- •5.At least 1 prior purine analogue or bendamustine containing therapy
- •6.Creatinine clearance =30ml/min or both
- •7.Hemoglobin > 9 g/dL; absolute neutrophil count (ANC) = 1.5 x 109/L and platelets (Plt) = 75 x 109/L unless cytopenia is caused by the underlying disease, i.e. no evidence of additional bone marrow dysfunction (e.g. myelodysplastic syndrome [MDS])
- •8.Life expectancy >6-8 months
- •9.Able and willing to provide written informed consent and to comply with the study protocol procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 29
排除标准
- •1.Prior Alogenic Bone Marrow Transplant
- •2.= 3 previous lines of chemotherapy and/or immunotherapy for the CLL.
- •3.Previous obinutuzumab-containing regimen.
- •4.Refractory CLL to bendamustine treatment (i.e. treatment failure or progression within 6 months of bendamustine-containing regimen).
- •5.Transformation of CLL to aggressive NHL (Richter’s transformation)
- •6.Active haemolytic anaemia
- •7.Inadequate liver function: NCICTC Grade 3 liver function tests (AST, ALT >5 x ULN for >2 weeks; Bilirubin >3 x ULN) unless due to underlying disease.
- •8.History of other malignancy which could affect compliance with the protocol or interpretation of results. Patients with a history of malignancy that has been treated but not with curative intent will be excluded, unless the malignancy has been in remission without treatment for = 2 years prior to enrolment. Patients with a history of adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with curative intent are eligible.
- •9.Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, severe arrhythmia, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).
- •10.Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis.
- •11.Regular treatment with corticosteroids during the 4 weeks prior to the start of Cycle 1, unless administered for indications other than lymphoma at a dose equivalent to = 30 mg/day prednisone
- •12.Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics, except if for tumor fever) within 4 weeks prior to the start of Cycle 1.
- •13.Patients with known infection with Human immunodeficiency virus (HIV) or Human T Cell Leukemia Virus 1 (HTLV-1).
- •14.Positive hepatitis serology:
- •a)Hepatitis B (HBV): Patients with positive serology for Hepatitis B defined as positivity for Hepatitis B surface antigen (HBsAg) or anti Hepatitis B core antibody (anti-HBc). Patients positive for anti-HBc may be included if Hepatitis B viral DNA is not detectable.
- •b)Hepatitis C (HCV): Patients with positive Hepatitis C serology unless HCV (RNA) is confirmed negative.
- •15.History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
- •16.Known sensitivity or allergy to murine products.
- •17.Known hypersensitivity to any of the study drugs
- •18.Women who are pregnant or lactating
- •19.Fertile men or women of childbearing potential unless: (1) surgically sterile or = 2 years after the onset of me
研究者
相似试验
尚未招募
不适用
Onderzoek naar de uitkomst van chemotherapie gevolgd door een lymfeklieroperatie en een gecombineerde behandeling van chemotherapie met uitwendige bestraling voor hoog-risico spier-ingroeiend blaaskanker (CHEMORAD-TRIAL)Bladder cancer, locally advanced disease, node positive disease, chemotherapy, lymph node dissection, chemoradiationNL-OMON27865The Netherlands Cancer Institute-Antoni van Leeuwenhoek HospitalPostbus 90203, 1006 BE, AmsterdamThe Netherlands50
已完成
2 期
PROSPECTIVE FASE-II TRIAL EVALUATING THE OUTCOME OF INDUCTION CHEMOTHERAPY FOLLOWED BY EXTENDED LYMPH NODE DISSECTION AND CHEMORADIATION FOR HIGH RISK INVASIVE BLADDER CANCER<br>'bladder cancer' and 'high-risk muscle invasive bladder cancer'100383641000499410038365NL-OMON43780Antoni van Leeuwenhoek Ziekenhuis50
已完成
2 期
A phase II study on the feasibility and efficacy of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancerrectal cancerJPRN-UMIN000023621Department of Surgery Kindai University Faculty of Medicine42
招募中
2 期
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL10025320lymphomaNL-OMON36830HOVO60
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation - HOVON 80 NHrelapsed B cell lymphomaMedDRA version: 8.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2006-002141-37-NLHOVON foundation35